Download PDF
Semin Liver Dis 2012; 32(04): 298-306
DOI: 10.1055/s-0032-1329898
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Using Human-Induced Pluripotent Stem Cells to Model Monogenic Metabolic Disorders of the Liver

Maria Paulina Ordonez
1   Department of Pediatric Gastroenterology, Hepatology and Nutrition, University of California, La Jolla, San Diego, California
,
Lawrence S.B. Goldstein
2   Department of Cellular and Molecular Medicine, University of California, La Jolla, San Diego, California
› Author Affiliations
Further Information

Publication History

Publication Date:
08 February 2013 (online)

    Permissions and Reprints

Abstract

A crucial problem in liver disease biology and a major obstacle to the development of new therapies is the inability to conduct mechanistic studies of live human hepatocytes. Liver tissue from patients is difficult to obtain and only reveals the disease aftermath, while animal models lack the significant genetic diversity of humans. Monogenic metabolic disorders of the liver are an ideal platform to explore the complex gene–environment interactions and the role of genetic variation in the onset and progression of liver disease. Human induced pluripotent stem cell (hIPSC) technology provides an unprecedented opportunity to generate live cellular models of disease for therapeutic candidate discovery and cell replacement therapy. In this review, we discuss the potential of hIPSC to increase our understanding of human disease with a focus on the current efforts to model metabolic diseases of the liver and to generate suitable populations of human hepatocytes for cell transplantation.

Keywords

human-induced pluripotent stem cells - hepatocyte differentiation - disease modeling - inherited liver metabolic disorders - cell transplantation
 

  • References

  • 1 Mayatepek E, Hoffmann B, Meissner T. Inborn errors of carbohydrate metabolism. Best Pract Res Clin Gastroenterol 2010; 24 (5) 607-618
    CrossrefPubMedGoogle Scholar
  • 2 Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56 (4) 952-964
    CrossrefPubMedGoogle Scholar
  • 3 Lerapetritou MG, Georgopoulos PG, Roth CM, Androulakis LP. Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational research. Clin Transl Sci 2009; 2 (3) 228-237
    CrossrefPubMedGoogle Scholar
  • 4 Lanpher B, Brunetti-Pierri N, Lee B. Inborn errors of metabolism: the flux from Mendelian to complex diseases. Nat Rev Genet 2006; 7 (6) 449-460
    PubMedGoogle Scholar
  • 5 Melum E, Franke A, Karlsen TH. Genome-wide association studies—a summary for the clinical gastroenterologist. World J Gastroenterol 2009; 15 (43) 5377-5396
    CrossrefPubMedGoogle Scholar
  • 6 Weber SL, Segal S, Packman W. Inborn errors of metabolism: psychosocial challenges and proposed family systems model of intervention. Mol Genet Metab 2012; 105 (4) 537-541
    CrossrefPubMedGoogle Scholar
  • 7 Sokal EM. Liver transplantation for inborn errors of liver metabolism. J Inherit Metab Dis 2006; 29 (2-3) 426-430
    CrossrefPubMedGoogle Scholar
  • 8 Meyburg J, Hoffmann GF. Liver cell transplantation for the treatment of inborn errors of metabolism. J Inherit Metab Dis 2008; 31: 164-172
    CrossrefPubMedGoogle Scholar
  • 9 Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23 (11) 1635-1648
    CrossrefPubMedGoogle Scholar
  • 10 van der Worp HB, Howells DW, Sena ES , et al. Can animal models of disease reliably inform human studies?. PLoS Med 2010; 7 (3) e1000245
    CrossrefPubMedGoogle Scholar
  • 11 Colman A, Dreesen O. Pluripotent stem cells and disease modeling. Cell Stem Cell 2009; 5 (3) 244-247
    CrossrefPubMedGoogle Scholar
  • 12 Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010; 16 (11) 1210-1214
    CrossrefPubMedGoogle Scholar
  • 13 Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 2002; 5 (7) 633-639
    CrossrefPubMedGoogle Scholar
  • 14 Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010; 66 (5) 646-661
    CrossrefPubMedGoogle Scholar
  • 15 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126 (4) 663-676
    CrossrefPubMedGoogle Scholar
  • 16 Takahashi K, Tanabe K, Ohnuki M , et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131 (5) 861-872
    CrossrefPubMedGoogle Scholar
  • 17 Park I-H, Zhao R, West JA , et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451 (7175) 141-146
    CrossrefPubMedGoogle Scholar
  • 18 Cohen DE, Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet 2011; 12 (4) 243-252
    CrossrefPubMedGoogle Scholar
  • 19 Gurdon JB, Melton DA. Nuclear reprogramming in cells. Science 2008; 322 (5909) 1811-1815
    CrossrefPubMedGoogle Scholar
  • 20 Ying QL, Wray J, Nichols J , et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453 (7194) 519-523
    CrossrefPubMedGoogle Scholar
  • 21 Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function?. Cell 2001; 105 (7) 829-841
    CrossrefPubMedGoogle Scholar
  • 22 Izpisúa Belmonte JC, Ellis J, Hochedlinger K, Yamanaka S. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet 2009; 10 (12) 878-883
    PubMedGoogle Scholar
  • 23 Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481 (7381) 295-305
    CrossrefPubMedGoogle Scholar
  • 24 Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2010; 24 (20) 2239-2263
    CrossrefPubMedGoogle Scholar
  • 25 Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3 (6) 595-605
    CrossrefPubMedGoogle Scholar
  • 26 Park I-H, Arora N, Huo H , et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134 (5) 877-886
    CrossrefPubMedGoogle Scholar
  • 27 Maehr R, Chen S, Snitow M , et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A 2009; 106 (37) 15768-15773
    CrossrefPubMedGoogle Scholar
  • 28 Mou X, Wu Y, Cao H , et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res Ther 2012; 3 (2) 14
    CrossrefPubMedGoogle Scholar
  • 29 Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I , et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Molecular Medicine 2012; 4: 1-16
    CrossrefPubMedGoogle Scholar
  • 30 Schwartz RE, Trehan K, Andrus L , et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012; 109 (7) 2544-2548
    CrossrefPubMedGoogle Scholar
  • 31 Yusa K, Rashid ST, Strick-Marchand H , et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011; 478 (7369) 391-394
    CrossrefPubMedGoogle Scholar
  • 32 Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103 (8) 2136-2141 , quiz 2142
    CrossrefPubMedGoogle Scholar
  • 33 Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008; 3: 16
    CrossrefPubMedGoogle Scholar
  • 34 Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology 2007; 45 (5) 1313-1323
    CrossrefPubMedGoogle Scholar
  • 35 Petit I, Kesner NS, Karry R , et al. Induced pluripotent stem cells from hair follicles as a cellular model for neurodevelopmental disorders. Stem Cell Res (Amst) 2012; 8 (1) 134-140
    CrossrefPubMedGoogle Scholar
  • 36 Yan X, Qin H, Qu C, Tuan RS, Shi S, Huang GT. iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. Stem Cells Dev 2010; 19 (4) 469-480
    CrossrefPubMedGoogle Scholar
  • 37 Kim K, Doi A, Wen B , et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467 (7313) 285-290
    CrossrefPubMedGoogle Scholar
  • 38 Nishino K, Toyoda M, Yamazaki-Inoue M , et al. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet 2011; 7 (5) e1002085
    CrossrefPubMedGoogle Scholar
  • 39 Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009; 5 (6) 584-595
    CrossrefPubMedGoogle Scholar
  • 40 Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458 (7239) 771-775
    CrossrefPubMedGoogle Scholar
  • 41 Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009; 27 (11) 2667-2674
    CrossrefPubMedGoogle Scholar
  • 42 Cheng L, Hansen NF, Zhao L , et al; NISC Comparative Sequencing Program. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 2012; 10 (3) 337-344
    CrossrefPubMedGoogle Scholar
  • 43 Woltjen K, Michael IP, Mohseni P , et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458 (7239) 766-770
    CrossrefPubMedGoogle Scholar
  • 44 Boulting GL, Kiskinis E, Croft GF , et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 2011; 29 (3) 279-286
    CrossrefPubMedGoogle Scholar
  • 45 Miura K, Okada Y, Aoi T , et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009; 27 (8) 743-745
    CrossrefPubMedGoogle Scholar
  • 46 Urnov FD, Miller JC, Lee Y-L , et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435 (7042) 646-651
    CrossrefPubMedGoogle Scholar
  • 47 Hockemeyer D, Wang H, Kiani S , et al. Genetic engineering of human pluripotent cells using TALE nuclease. Nat Biotechnol 2011; 29 (8) 731-734
    CrossrefPubMedGoogle Scholar
  • 48 Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet 1990; 6 (6) 182-186
    CrossrefPubMedGoogle Scholar
  • 49 Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995; 23 (10) 1008-1021
    PubMedGoogle Scholar
  • 50 Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352 (21) 2211-2221
    CrossrefPubMedGoogle Scholar
  • 51 Hamazaki T, Iiboshi Y, Oka M , et al. Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS Lett 2001; 497 (1) 15-19
    CrossrefPubMedGoogle Scholar
  • 52 Chinzei R, Tanaka Y, Shimizu-Saito K , et al. Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation into functional hepatocytes. Hepatology 2002; 36 (1) 22-29
    CrossrefPubMedGoogle Scholar
  • 53 Touboul T, Hannan NRF, Corbineau S , et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010; 51 (5) 1754-1765
    CrossrefPubMedGoogle Scholar
  • 54 Cai J, Zhao Y, Liu Y , et al. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 2007; 45 (5) 1229-1239
    CrossrefPubMedGoogle Scholar
  • 55 Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008; 132 (4) 661-680
    CrossrefPubMedGoogle Scholar
  • 56 Irion S, Nostro MC, Kattman SJ, Keller GM. Directed differentiation of pluripotent stem cells: from developmental biology to therapeutic applications. Cold Spring Harb Symp Quant Biol 2008; 73: 101-110
    CrossrefPubMedGoogle Scholar
  • 57 Behbahan IS, Duan Y, Lam A , et al. New approaches in the differentiation of human embryonic stem cells and induced pluripotent stem cells toward hepatocytes. Stem Cell Rev 2011; 7 (3) 748-759
    CrossrefPubMedGoogle Scholar
  • 58 Gai H, Nguyen DM, Moon YJ , et al. Generation of murine hepatic lineage cells from induced pluripotent stem cells. Differentiation 2010; 79 (3) 171-181
    CrossrefPubMedGoogle Scholar
  • 59 Duan Y, Ma X, Zou W , et al. Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells 2010; 28 (4) 674-686
    CrossrefPubMedGoogle Scholar
  • 60 Asgari S, Moslem M, Bagheri-Lankarani K , et al. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev 2011; Nov 11. [Epub ahead of print]
    PubMedGoogle Scholar
  • 61 D'Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, Baetge EE. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol 2005; 23 (12) 1534-1541
    CrossrefPubMedGoogle Scholar
  • 62 Farzaneh Z, Pournasr B, Ebrahimi M, Aghdami N, Baharvand H. Enhanced functions of human embryonic stem cell-derived hepatocyte-like cells on three-dimensional nanofibrillar surfaces. Stem Cell Rev 2010; 6 (4) 601-610
    CrossrefPubMedGoogle Scholar
  • 63 Ek M, Söderdahl T, Küppers-Munther B , et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 2007; 74 (3) 496-503
    CrossrefPubMedGoogle Scholar
  • 64 Agarwal S, Holton KL, Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 2008; 26 (5) 1117-1127
    CrossrefPubMedGoogle Scholar
  • 65 Yamada T, Yoshikawa M, Kanda S , et al. In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green. Stem Cells 2002; 20 (2) 146-154
    CrossrefPubMedGoogle Scholar
  • 66 Basma H, Soto-Gutiérrez A, Yannam GR , et al. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 2009; 136 (3) 990-999
    CrossrefPubMedGoogle Scholar
  • 67 Song Z, Cai J, Liu Y , et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009; 19 (11) 1233-1242
    CrossrefPubMedGoogle Scholar
  • 68 Sullivan GJ, Hay DC, Park I-H , et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010; 51 (1) 329-335
    CrossrefPubMedGoogle Scholar
  • 69 Si-Tayeb K, Noto FK, Nagaoka M , et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010; 51 (1) 297-305
    CrossrefPubMedGoogle Scholar
  • 70 Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475 (7356) 390-393
    CrossrefPubMedGoogle Scholar
  • 71 Huang P, He Z, Ji S , et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475 (7356) 386-389
    CrossrefPubMedGoogle Scholar
  • 72 Willenbring H. A simple code for installing hepatocyte function. Cell Stem Cell 2011; 9 (2) 89-91
    CrossrefPubMedGoogle Scholar
  • 73 Eggenschwiler R, Loya K, Sgodda M, André F, Cantz T. Hepatic differentiation of murine disease-specific induced pluripotent stem cells allows disease modelling in vitro. Stem Cells Int 2011; 2011 (924782) 1-11
    PubMedGoogle Scholar
  • 74 Grompe M. Liver repopulation for the treatment of metabolic diseases. J Inherit Metab Dis 2001; 24 (2) 231-244
    CrossrefPubMedGoogle Scholar
  • 75 Perlmutter DH. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in α-1-antitrypsin deficiency. Cell Death Differ 2009; 16 (1) 39-45
    CrossrefPubMedGoogle Scholar
  • 76 Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol 2004; 286 (5) G851-G862
    CrossrefPubMedGoogle Scholar
  • 77 Perlmutter DH. The role of autophagy in alpha-1-antitrypsin deficiency: a specific cellular response in genetic diseases associated with aggregation-prone proteins. Autophagy 2006; 2 (4) 258-263
    PubMedGoogle Scholar
  • 78 Rashid ST, Corbineau S, Hannan N , et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120 (9) 3127-3136
    CrossrefPubMedGoogle Scholar
  • 79 Wilson MH, Coates CJ, George Jr AL. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 2007; 15 (1) 139-145
    CrossrefPubMedGoogle Scholar
  • 80 Kim A, Pyykko I. Size matters: versatile use of PiggyBac transposons as a genetic manipulation tool. Mol Cell Biochem 2011; 354 (1-2) 301-309
    CrossrefPubMedGoogle Scholar
  • 81 Mundy H, Lee PJ. The glycogen storage diseases. Curr Paediatr 2004; 14: 407-413
    CrossrefPubMedGoogle Scholar
  • 82 Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol 2007; 13 (18) 2541-2553
    PubMedGoogle Scholar
  • 83 Chou JY, Jun HS, Mansfield BC. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy. Nat Rev Endocrinol 2010; 6 (12) 676-688
    CrossrefPubMedGoogle Scholar
  • 84 Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 2008; 12 (2) 137-145
    CrossrefPubMedGoogle Scholar
  • 85 Wang DQ, Fiske LM, Carreras CT, Weinstein DA. Natural history of hepatocellular adenoma formation in glycogen storage disease type I. J Pediatr 2011; 159 (3) 442-446
    PubMedGoogle Scholar
  • 86 Di Rocco M, Calevo MG, Taro' M, Melis D, Allegri AE, Parenti G. Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease. Mol Genet Metab 2008; 93 (4) 398-402
    CrossrefPubMedGoogle Scholar
  • 87 Heller S, Worona L, Consuelo A. Nutritional therapy for glycogen storage diseases. J Pediatr Gastroenterol Nutr 2008; 47 (Suppl. 01) S15-S21
    CrossrefPubMedGoogle Scholar
  • 88 Wolfsdorf JI, Crigler Jr JF. Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. J Pediatr Gastroenterol Nutr 1999; 29 (2) 136-143
    CrossrefPubMedGoogle Scholar
  • 89 Ghosh A, Allamarvdasht M, Pan C-J , et al. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther 2006; 13 (4) 321-329
    CrossrefPubMedGoogle Scholar
  • 90 Chou JY, Mansfield BC. Gene therapy for type I glycogen storage diseases. Curr Gene Ther 2007; 7 (2) 79-88
    CrossrefPubMedGoogle Scholar
  • 91 Brunetti-Pierri N, Lee B. Gene therapy for inborn errors of liver metabolism. Mol Genet Metab 2005; 86 (1-2) 13-24
    CrossrefPubMedGoogle Scholar
  • 92 Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006; 29 (2-3) 431-435
    CrossrefPubMedGoogle Scholar
  • 93 Sjouke B, Kusters DM, Kastelein JJP, Hovingh GK. Familial hypercholesterolemia: present and future management. Curr Cardiol Rep 2011; 13 (6) 527-536
    CrossrefPubMedGoogle Scholar
  • 94 Fahed AC, Nemer GM. Familial hypercholesterolemia: the lipids or the genes?. Nutr Metab (Lond) 2011; 8 (1) 23
    CrossrefPubMedGoogle Scholar
  • 95 Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4 (4) 214-225
    CrossrefPubMedGoogle Scholar
  • 96 Wiegman A, Hutten BA, de Groot E , et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292 (3) 331-337
    CrossrefPubMedGoogle Scholar
  • 97 Liu ET. Expression genomics and drug development: towards predictive pharmacology. Brief Funct Genomics Proteomics 2005; 3 (4) 303-321
    CrossrefPubMedGoogle Scholar
  • 98 Ghodsizadeh A, Taei A, Totonchi M , et al. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev 2010; 6 (4) 622-632
    CrossrefPubMedGoogle Scholar
  • 99 Sokal EM, Goldstein D, Ciocca M , et al; End-Stage Liver Disease Working Group. End-stage liver disease and liver transplant: current situation and key issues. J Pediatr Gastroenterol Nutr 2008; 47 (2) 239-246
    CrossrefPubMedGoogle Scholar
  • 100 Singal AK, Duchini A. Liver transplantation in acute alcoholic hepatitis: Current status and future development. World J Hepatol 2011; 3 (8) 215-218
    CrossrefPubMedGoogle Scholar
  • 101 Feng S, Si M, Taranto SE , et al. Trends over a decade of pediatric liver transplantation in the United States. Liver Transpl 2006; 12 (4) 578-584
    CrossrefPubMedGoogle Scholar
  • 102 McDiarmid SV, Goodrich NP, Harper AM, Merion RM. Liver transplantation for status 1: the consequences of good intentions. Liver Transpl 2007; 13 (5) 699-707
    CrossrefPubMedGoogle Scholar
  • 103 Piscaglia AC, Campanale M, Gasbarrini A, Gasbarrini G. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int 2010; 2010 (259461) 1-10
    PubMedGoogle Scholar
  • 104 Mizuguchi T, Mitaka T, Katsuramaki T, Hirata K. Hepatocyte transplantation for total liver repopulation. J Hepatobiliary Pancreat Surg 2005; 12 (5) 378-385
    CrossrefPubMedGoogle Scholar